HIV / AIDS: a look at the problem
- Authors: Amlaev K.R1
-
Affiliations:
- Stavropol State Medical University
- Issue: Vol 32, No 2 (2021)
- Pages: 37-41
- Section: Articles
- URL: https://journals.eco-vector.com/0236-3054/article/view/114376
- DOI: https://doi.org/10.29296/25877305-2021-02-07
- ID: 114376
Cite item
Abstract
The article in the format of a mini-lecture is devoted to the problem of HIV Infection. Data on the history of the virus in the 20s of the last century are presented. The mechanisms of infection and the risks of infection with the virus through various actions are considered. The main modern approaches to the prevention and treatment of the disease are briefly described, and the concept of the AIDS stage Is given.
Keywords
Full Text
References
- Sharp P.M., Hahn В.Н. Origins of HIV and the AIDS pandemic. Cold Spring Harb PerspectMed. 2011; 1 (1): a006841. doi: 10.1101/cshperspect.a006841
- Hymes K.B., Cheung Т., Greene J.B. et al. Kaposi’s sarcoma in homosexual men-а report of eight cases. Lancet. 1981; 2 (8247): 598-600. DOI: 10.1016/ s0140-6736(81)92740-9
- Masur H., Michelis M.A., Greene J.B. et al. An outbreak of community-acquired Pneumocystis carinii pneumonia: initial manifestation of cellular immune dysfunction. N Engl J Med. 1981; 305 (24): 1431-8. DOI: 10.1056/ NEJM198112103052402
- Plot P., Quinn T.C., Taelman H. et al. Acquired immunodeficiency syndrome in a heterosexual population in Zaire. Lancet. 1984; 2 (8394): 65-9. DOI: 10.1016/ s0140-6736(84)90241-1
- Van de Perre P., Rouvroy D., Lepage P. et al. Acquired immunodeficiency syndrome in Rwanda. Lancet. 1984; 2 (8394): 62-5. doi: 10.1016/s0140-6736(84)90240-x
- Faria N.R., Rambaut A., Suchard M.A. et al. HIV Epidemiology. The early spread and epidemic ignition of HIV-1 in human populations. Science. 2014; 346 (6205): 56-61. doi: 10.1126/science.1256739
- Smith D.M., Richman D.D., Little S.J. HIV superinfection. J Infect Dis. 2005; 192 (3): 438-44. doi: 10.1086/431682
- UNAIDS (2015). AIDS by the numbers. Available at: httpJ/wm/.unaids.org/ en/resources/documents/2015/AIDS_by_the_numbers_2015 [Accessed 15.06.2020].
- World Health Organization. Antiretroviral drugs for treating pregnant women and preventing HIV Infection in infants: recommendations for a public health approach (2013 version). Geneva, Switzerland: WHO Press; 2013.
- World Health Organization. Guidelines on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Geneva: World Health Organization; 2015. URL: httpJ/www.who.int/hij/pub/guidelines/earlyrelease-arv/ en/
- World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection, second edition, June 2016. URL: httpJ/www.who.int/hiv/pub/an//arv-201 в/еп/
- UNAIDS (2013). HIV in Asia and the Pacific. Available at: httpJ/www.unaids. org/en/resources/documents/2013/20131119_HIV-Asia-Padfic
- Saravanan S., Velu V., Kumarasamy N. et al. Coinfection of hepatitis В and hepatitis С virus in HIV-infected patients in south India. World J Gastroenterol. 2007; 13 (37): 5015-20. doi: 10.3748/wjg.v13.137.5015
- Khalsa J.H., Elkashef A. Interventions for HIV and hepatitis С virus infections in recreational drug users. Clin Infect Dis. 2010; 50 (11): 1505-11. doi: 10.1086/652447
- Becerra J.C., Bildstein L.S., Gach J.S. Recent Insights into the HIV/AIDS Pandemic. Microbial Cell. 2016; 3 (9): 451-75. doi: 10.15698/mic2016.09.529
- Grulich A.E., Zablotska I. Commentary: probability of HIV transmission through anal intercourse. Int J Epidemiol. 2010; 39 (4): 1064-5. doi: 10.1093/ije/ dyql01
- Boily M.C., Baggaley R.F., Wang L. et al. Heterosexual risk of HIV-1 Infection per sexual act: systematic review and meta-analysis of observational studies. Lancet Infect Dis. 2009; 9 (2): 118-29. doi: 10.1016/S1473-3099(09)70021-0
- Keele B.F., Estes J.D. Barriers to mucosal transmission of immunodeficiency viruses. Blood. 2011; 118 (4): 839-46. doi: 10.1182/blood-2010-12-325860
- Patel P., Borkowf C.B., Brooks J.T. et al. Estimating per-act HIV transmission risk: a systematic review. AIDS. 2014; 28 (10): 1509-19. DOI: 10.1097/ QAD.0000000000000298
- QuinnT.C.,WawerM.J., Sewankambo N. etal. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med. 2000; 342 (13): 921-9. DOI: 10.1056/ NEJM200003303421303
- Baeten J.M., Kahle E., Lingappa J.R. et al. Partners in Prevention HSVHIVTST Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission. Sd Transl Med. 2011; 3 (77): 77ra29. doi: 10.1126/scitranslmed.3001888
- Galvin S.R., Cohen M.S. The role of sexually transmitted diseases in HIV transmission. Nat Rev Microbiol. 2004; 2 (1): 33-42. doi: 10.1038/nrmicro794
- Laga М., Piot P. Prevention of sexual transmission of HIV: real results, science progressing, societies remaining behind. AIDS. 2012; 26 (10): 1223-9. doi: 10.1097/QAD.0b013e32835462b8
- Marrazzo J.M., Cates W. Interventions to prevent sexually transmitted infections, including HIV infection. Clin Infect Dis. 2011; 53 (Suppl. 3): S64-78. doi: 10.1093/cid/cir€95
- Chang L.W., Serwadda D., Quinn T.C. et al. Combination implementation for HIV prevention: moving from clinical trial evidence to population-level effects. Lancet Infect Dis. 2013; 13 (1): 65-76. doi: 10.1016/S1473-3099(12)70273-6
- Volk J.E., Marcus J.L., Phengrasamy T. et al. No new HIV infections with increasing use of HIV preexposure prophylaxis in a clinical practice setting. Clin Infect Dis. 2015; 61 (10): 1601-3. doi: 10.1093/cid/civ778
- Coffin J.t Swanstrom R. HIV pathogenesis: dynamics and genetics of viral populations and infected cells. Cold Spring Harb Perspect Med. 2013; 3 (1): a012526. doi: 10.1101/cshperspect.a012526
- Stacey A.R., Norris P.J., Qin L. et al. Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis В and С virus infections. J Virol. 2009; 83 (8): 3719-33. DOI: 10.1128/ JVI.01844-08
- Pincus J.M., Crosby S.S., Losina E. et al. Acute human immunodeficiency virus infection in patients presenting to an urban urgent care center. Clin Infect Dis. 2003; 37 (12): 1699-704. doi: 10.1086/379772 '
- Tokman S., Huang L. Evaluation of respiratory disease. Clin Chest Med. 2013; 34 (2): 191-204. doi: 10.1016/j.ccm.2013.02.005
- Janoff E.N., Breiman R.F., Daley C.L. et al. Pneumococcal disease during HIV infection. Epidemiologic, clinical, and immunologic perspectives. Ann Intern Med. 1992; 117 (4): 314-24. doi: 10.7326/0003-4819-117-4-314
- Hirschtick R.E., Glassroth J., Jordan M.C. et al. Bacterial pneumonia in persons infected with the human immunodeficiency virus. Pulmonary Complications of HIV Infection Study Group. N Engl J Med. 1995; 333 (13): 845-51. DOI: 10.1056/ NEJM199509283331305
- Broder S. The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. Antiviral Res. 2010; 85 (1): 1-18. DOI: 10.1016/j. antlviral.2009.10.002
- Kulpa DA., Chomont N. HIV persistence in the setting of antiretroviral therapy: when, where and how does HIV hide? J Virus Erad. 2015; 1 (2): 59-66.
- Guerrero M.L.F., Rivas P., Molina M. et al. Long-term follow-up of asymptomatic HIV-infected patients who discontinued antiretroviral therapy. Clin Infect Dis. 2005; 41 (3): 390-4. doi: 10.1086/431487
- Ford N., Calmy A., Hurst S. When to start antiretroviral therapy in resource-limited settings: a human rights analysis. BMC Int Health Hum Rights. 2010; 10: 6. doi: 10.1186/1472-698X-10-6
- Deeks S.G. Determinants of virological response to antiretroviral therapy: Implications for long-term strategies. Clin Infect Dis. 2000; 30: S177-S184. doi: 10.1086/313855
- Lee P.K., KiefferT.L., Siliciano R.F. et al. HIV-1 viral load blips are of limited clinical significance. JAntimicrob Chemother. 2006; 57 (5): 803-5. DOI: 10.1093/ jac/dkl092
- Bertozzi S., Padian N.S., Wegbreit J. et al. HIV/AIDS Prevention and Treatment. Disease Control Priorities in Developing Countries. 2“ Ed. 2006; p. 331-69.
- Volk J.E., Marcus J.L., Phengrasamy T. et al. No New HIV Infections with Increasing Use of HIV Preexposure Prophylaxis in a Clinical Practice Setting. Clin Infect Dis. 2015; 61 (10): 1601-3. doi: 10.1093/cid/civ778
- Sabin С A., Phillips A.N. Should HIV therapy be started at a CD4 cell count above 350 cells/mu I in asymptomatic HIV-1-infected patients? Curr Opln Infect Dis. 2009; 22 (2): 191-7. doi: 10.1097/0c0.0b013e328326cd34
- Jain V., Deeks S.G. When to start antiretroviral therapy. Curr HIV/AIDS Rep. 2010; 7 (2): 60-8. doi: 10.1007/s11904-010-0044-6
- Franco R.A., Saag M.S. When to start antiretroviral therapy: as soon as possible. BMC Med. 2013; 11:147. doi: 10.1186/1741-7015-11-148
- Lundgren J.D., Babiker A.G., Gordin F.M. et al. When to start antiretroviral therapy: the need for an evidence base during early HIV infection. BMC Med. 2013; 11:148. https://d0i.0rg/l 0.1186/1741-7015-11 -148
- Group TAS: Danel C., Moh R., Gabillard D. et al. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. N Engl J Med. 2015; 373 (9): 808-22. doi: 10.1056/NEJMoa1507198
- Nachega J.B., Parienti J.J., Uthman O.A. et al. Lower Pill Burden and Once-Daily Antiretroviral Treatment Regimens for HIV Infection: A Meta-Analysis of Randomized Controlled Trials. Clin Infect Dis. 2014; 58 (9): 1297-307. doi: 10.1093/cid/ciu046
- May M.T., Gompels М., Delpech V. et al. Study UKCHC. Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy. AIDS. 2014; 28 (8): 1193-202. DOI: 10.1097/ QAD.0000000000000243
- Liu C., Ma X., Liu B. et al. HIV-1 functional cure: will the dream come true? BMC Med. 2015; 13: 284. doi: 10.1186/s12916-015-0517-y